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OBJECTIVES We evaluated the incidence and predictors of sudden death after atrioventricular (AV) node
ablation and pacemaker implantation.
BACKGROUND Sudden death may occur after radiofrequency catheter ablation of the AV node and
pacemaker implantation in patients with atrial fibrillation (AF). Whether it is related to the
procedure or to pre-existing heart disease remains unclear.
METHODS All patients who had radiofrequency catheter ablation of the AV node and pacemaker
implantation for rate control of medically refractory AF were identified retrospectively and
observed prospectively. All patients with sudden death after ablation were identified. The
relationship between the procedure and sudden death was defined on the basis of the time
between the two as “likely,” “possibly” or “unlikely.”
RESULTS Of 334 consecutive patients with AF who underwent AV node ablation, nine had sudden
death after the ablation. Four patients (1.2%) had sudden death likely related to the procedure: in
3 patients, arrest occurred within 48 h after the procedure; in one patient, arrest occurred four days
after the procedure. In three other patients (0.9%), sudden death was possibly related to the
procedure because the event occurred within three months afterward. The remaining two deaths
were unrelated to the procedure. Diabetes, New York Heart Association functional class (II),
preprocedure ventricular arrhythmia, mitral or aortic stenosis, aortic regurgitation and chronic
obstructive pulmonary disease were independent predictors for sudden death.
CONCLUSIONS Sudden death likely or possibly related to catheter ablation occurred in 7 of 334 patients
(2.1%). Risk of sudden death is highest within two days after the procedure. (J Am Coll
Cardiol 2002;40:105–10) © 2002 by the American College of Cardiology Foundation
Catheter ablation of the atrioventricular (AV) node by
radiofrequency energy and permanent pacemaker implanta-
tion is an alternative nonpharmacologic treatment for con-
trolling the ventricular rate in symptomatic patients with
atrial fibrillation (AF) for whom drug therapy has failed
(1–4). Although AV node ablation does not eliminate AF,
several studies have reported a reduction of symptoms and
improvement in the quality of life, exercise tolerance and left
ventricular function (4–8). Moreover, we recently demon-
strated that treatment with AV node ablation and perma-
nent pacemaker implantation does not have a negative effect
on long-term overall survival when compared with pharma-
cologic treatment (9).
Although AV node ablation and permanent pacemaker
implantation is considered effective and safe treatment for
patients who have AF, life-threatening complications, such
as ventricular arrhythmia and sudden death, have been
reported to occur after the procedure (10–15). Previous studies
showed that the incidence of these complications ranged from
3.1% to 6.7% (7,12,13). The annual rate of sudden death has
been estimated to range from 1.9% to 3.7% (13,15). Because of
the high prevalence of pre-existing cardiovascular disease
(CVD) and the likely presence of an associated arrhythmo-
genic substrate in patients undergoing AV node ablation and
pacemaker implantation for AF, it has been difficult to distin-
guish cardiac arrest secondary to pre-existing underlying dis-
ease versus procedure-related cardiac arrest.
In this study, we evaluated the incidence and predictors of
sudden death after AV node ablation and pacemaker implan-
tation in patients with AF that was refractory to drug therapy.
Individual events were defined to identify the following: 1)
sudden death likely related to the procedure; 2) sudden death
possibly related to the procedure; 3) sudden death unlikely
related to the procedure; and 4) predictors of sudden death.
METHODS
Study population. Patients included in this study were all
those with a history of AF who had radiofrequency AV
node ablation and pacemaker implantation from July 1990
through December 1998 at Mayo Clinic (Rochester, Min-
nesota). Patients with indications for AV node ablation
include symptomatic patients with paroxysmal or chronic
AF refractory to pharmacologic therapy for maintaining
sinus rhythm or ventricular rate control. Patients who had
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direct current (DC) AV node ablation were excluded from
the study.
Definitions. Sudden death was defined as death that was
witnessed and the patient died within 1 h of the onset of
symptoms or death that occurred within 1 h from when the
patient was last seen to when the body was found. The
death was defined as being “likely,” “possibly” or “unlikely”
related to the procedure. If sudden death occurred within
48 h after the procedure or occurred at any time after the
procedure in the absence of any CVD, the cause was defined
as “likely” related to the procedure. If sudden death occurred
between two days and three months after the procedure in
the presence of CVD, the cause was defined as “possibly”
related to the procedure. If sudden death occurred later than
three months after the procedure in the presence of CVD,
the cause was defined as “unlikely” related to the procedure.
Data collection. Data were collected from a centralized
system that provided complete records of AV node ablation
and pacemaker implantation in patients observed at Mayo
Clinic. These records provided a detailed history and
diagnosis for all outpatient encounters, including emergency
room visits, house and nursing home calls, as well as data
recorded for inpatient care, death certificates and autopsies.
Follow-up. The follow-up period began at the time of the
ablation procedure and ended in January 1999 or at the time
of death. Patients were observed in the pacemaker clinic at
three-month intervals for the first year. Thereafter, a yearly
survey was conducted. Causes of death were determined
from review of hospital records, death certificates and phone
calls to the local physician or family members. Follow-up
was complete for all patients.
AV node ablation and pacemaker implantation. Radio-
frequency ablation of the AV node was performed by
standard techniques in the electrophysiology laboratory (9).
Complete AV block was achieved in all patients. The
pacemaker was implanted the next day or immediately after
ablation (since 1994). Seven patients (2%) required a left-
sided approach to achieve AV block, and 24 patients (7%)
required a second or third procedure because of recurrent
AV conduction after the first attempt. A rate-responsive
ventricular pacemaker (VVIR) was implanted when the
patient had AF at the time of the procedure and when
cardioversion to restore and maintain sinus rhythm was no
longer attempted. A dual-chamber, rate-adaptive pace-
maker (DDDR) was implanted when the patient had a
history of paroxysmal AF and had sinus rhythm at the time
of the procedure or sinus rhythm was restored by cardio-
version. Before 1997, the lower pacing rate was pro-
grammed at 60 beats/min for temporary or permanent
pacemakers after AV block. Since 1997, the lower pacing
rate was set at 90 beats/min immediately after ablation and
was gradually decreased by 10 beats/min monthly to 60
beats/min.
Statistical analysis. Data are presented as percentages or as
means  SD. A p value 0.05 was considered significant.
Univariate and multivariate associations of baseline variables
with sudden death were assessed using logistic regression
analysis (16). The following variables were considered po-
tential risk factors: demographic features (age and gender),
clinical history (syncope, angina, congestive heart failure
[CHF] and New York Heart Association [NYHA] func-
tional class), heart disease (ischemic heart disease, cardio-
myopathy and valvular heart disease) and associated clinical
conditions (diabetes mellitus [DM], chronic obstructive
pulmonary disease [COPD], cerebral vascular disease, hy-
pertension and cancer). Significant univariate factors are
presented as point estimates and 95% confidence intervals of
the risk ratios. The multivariate model for risk factor
analysis was not constructed because of the low number of
events.
RESULTS
Demographics. A total of 334 patients with AF (175 men
and 159 women) who underwent AV node ablation and
pacemaker implantation at Mayo Clinic from 1990 through
1998 were included in this study (Table 1). The mean age of
patients in the study group was 68  11 years (range, 32 to
95 years) at the time of ablation and pacing. Patients were
observed for a mean of 36 26 months (range, 3 days to 99
months; median, 33 months).
Classification of sudden death. Nine patients (six women
and three men; mean age, 68  7 years; range, 56 to 78
years) had sudden death after the ablation (Table 2).
According to our definitions, four patients had sudden
death likely related to the procedure because the event
occurred within 48 h of the procedure in three cases, and
one patient had sudden death four days after the procedure
in the absence of any CVD. Sudden death in three patients
was possibly related to the procedure because the event
occurred between two days and three months after the
procedure and in the presence of CVD. Another two
patients died suddenly at 27 and 43 months after the
procedure, and both had underlying structural heart disease.
Therefore, we considered their deaths as unlikely related to
the procedure.
Sudden death likely or possibly related to ablation. Of
the 9 patients who had sudden death, 7 (2.1%; 5 women and
2 men; mean age, 67  8 years; range, 56 to 78 years) had
arrests that were likely or possibly related to the procedure
(timing of the event after the procedure: mean, 10 9 days;
Abbreviations and Acronyms
AF  atrial fibrillation
AV  atrioventricular
CHF  congestive heart failure
COPD  chronic obstructive pulmonary disease
CVD  cardiovascular disease
DC  direct current
DM  diabetes mellitus
NYHA  New York Heart Association
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range, 1 to 35 days). The patients’ clinical characteristics are
summarized in Tables 1 and 2. Baseline characteristics of
these seven patients were not significantly different from
those of the overall study cohorts except for the history of
ventricular rhythm disturbances and COPD. Ventricular
rhythm disturbances include previously documented prema-
ture ventricular complexes, nonsustained ventricular tachy-
cardia and accelerated idioventricular rhythm.
Six of these seven patients had structural heart disease.
Ventricular arrhythmia was present in four of the seven
patients before the ablation (two with frequent premature
ventricular complexes, i.e., 10/h; two with nonsustained
ventricular tachycardia). The circumstances of the sudden
deaths and the clinical outcomes are shown in Figure 1. Six
of the seven patients had AF at the time of the ablation.
Among those six patients, the mean heart rate was 112 17
beats/min (range, 90 to 131 beats/min) before the ablation
and 39  25 beats/min (range, 0 to 75 beats/min) after
ablation. An escape rhythm was documented in six of the
seven patients immediately after AV node ablation. The
Q-Tc interval of the escape rhythm after ablation (mean,
440  65 ms) was not significantly prolonged compared
with the interval before ablation (mean, 438  55 ms) (p 
0.96). All except one patient (pacing rate, 90 beats/min) had
the lower pacing rate programmed at 60 beats/min imme-
diately after ablation. The initiating rhythm at the time of
cardiac arrest was documented in five patients: ventricular
fibrillation in four patients and polymorphic ventricular
tachycardia in one patient. The rhythm was not docu-
mented in the remaining two patients. Two patients died at
the time of cardiac arrest; five patients were resuscitated
acutely, but three of them died within two months after
arrest. The two survivors were alive at 35 and 39 months of
follow-up after the cardiac arrest.
Predictors for sudden death. The following were indepen-
dent predictors for sudden death in patients with AF after
AV node ablation and permanent pacing: DM, NYHA
functional class (II), preablation ventricular arrhythmia,
mitral stenosis, aortic stenosis, aortic regurgitation and
COPD (Table 3). The following were not independent
predictors for sudden death in this population: age, gender,
cardiac disease, cardiac surgery, hypertension, antiarrhyth-
mic drug therapy, duration of AF, diagnosis of paroxysmal
or chronic AF, low left ventricular ejection fraction, ablation
time, Q-Tc interval, bundle branch block, cycle length or
duration of AF and pacing mode.
Sudden death unlikely related to ablation. During the
long-term follow-up, two patients died suddenly and unex-
Table 1. Baseline Characteristics of Patients With AF Who Had AV Node Ablation and
Pacemaker Implantation From July 1990 Through December 1998*†
Characteristics
Without Sudden Death
(n  327)
With Sudden Death
(n  7) p Value
Age at ablation, yrs 68  11 67  8 0.71
Mean follow-up, months 36  26 11  14 0.03
Chronic AF 53 86 0.13
Paroxysmal AF 47 14 0.46
No. of antiarrhythmic drugs (preablation) 4.5  1.9 3.4  1.5 0.14
Prior coronary artery bypass graft 18 14 0.81
Prior cardiac valve surgery 17 29 0.44
CAD 45 43 0.92
Previous myocardial infarction 28 29 0.95
LVEF 0.47  0.17 0.49  0.18 0.84
LVEF 0.40 37 29 0.64
NYHA functional class 1.3  0.7 2  1.3 0.03
CHF (NYHA functional class II) 21 43 0.18
Left ventricular hypertrophy 9 14 0.97
Nonischemic cardiomyopathy 16 14 0.70
Mitral stenosis 10 43 0.02
Aortic stenosis 12 43 0.03
Aortic regurgitation 30 86 0.02
Concomitant sinus node dysfunction 18 0 0.96
Ventricular rhythm disturbances 13 57 0.005
Hypertension 46 57 0.55
Hyperlipidemia 36 14 0.27
DM 18 57 0.02
COPD 30 86 0.01
History of malignancy 20 29 0.57
Renal disease 13 0 0.97
Liver failure 3 0 0.98
*Of the 334 patients (175 men; 159 women), 9 (3 men; 6 women) had sudden death after the procedure, and 7 of the 9 (2 men;
5 women) had cardiac arrests that were likely or possibly related to the procedure (p  0.22); †Continuous data are expressed
as mean  SD; categorical data, as percentage of patients.
AF  atrial fibrillation; AV  atrioventricular; CAD  coronary artery disease; CHF  congestive heart failure; COPD 
chronic obstructive pulmonary disease; DM diabetes mellitus; LVEF left ventricular ejection fraction; NYHA New York
Heart Association.
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pectedly several months after the procedure. Both patients
had ischemic heart disease. One was a 69-year-old man with
coronary artery disease, cardiomyopathy, hypertension and
low left ventricular ejection fraction (0.30) who died 43
months after the ablation. The second patient was a
75-year-old woman with coronary artery disease and hyper-
tension who died 27 months after the ablation. Pacemaker
malfunction was not detected at the last follow-up exami-
nation before death. Thus, these patients were considered as
having sudden death that was unlikely related to the
ablation procedure.
Within the total study cohort, 74 patients had died at the
time of latest follow-up. A cardiac cause of death was
documented in 47 patients (64%). The most common cause
of death was CHF, which occurred in 24 patients (32%).
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Figure 1. Outcome after sudden death in patients with atrial fibrillation
after atrioventricular node ablation and permanent pacing. CHF 
congestive heart failure; VF  ventricular fibrillation; VT  ventricular
tachycardia.
Table 3. Predictors for Sudden Death Likely or Possibly
Related to AV Node Ablation and Permanent Pacing in
Patients With AF
Predictor
Risk
Ratio
95%
Confidence
Interval
p
Value
DM 6.06 1.32–27.78 0.02
Ventricular rhythm disturbance 8.81 1.91–40.71 0.005
NYHA functional class II 2.14 1.07–4.28 0.03
Mitral stenosis 6.46 1.39–30.10 0.02
Aortic stenosis 5.38 1.16–24.93 0.03
Aortic regurgitation 12.00 1.43–101.06 0.02
COPD 14.23 1.69–119.71 0.01
Abbreviations as in Table 1.
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DISCUSSION
Main findings. In this clinical follow-up study of radiofre-
quency catheter ablation of the AV node and permanent
pacemaker implantation in patients with medically refrac-
tory AF, the major findings include the following: 1) sudden
death likely related to the procedure occurred in four
patients (1.2%); 2) sudden death possibly related to the
procedure was documented in three patients (0.9%); 3) the
highest risk of sudden death was within 48 h after the
ablation; and 4) DM, NYHA functional class (II), ventric-
ular arrhythmia, mitral stenosis, aortic stenosis, aortic regurgi-
tation and COPD were independent predictors for early
sudden death. Although the overall incidence of sudden death
related to the procedure is low, our data support the recom-
mendation that in-hospital monitoring for a minimum of two
days after the ablation and pacemaker implantation should be
considered for patients with predictors of increased risk.
Sudden death after AV node ablation and pacemaker
implantation. In a nonrandomized prospective, interna-
tional, multicenter study, sudden death occurred in 3.8% of
patients within the first year after DC catheter ablation of
the AV junction (17). In another study, one of 17 patients
who underwent radiofrequency ablation died suddenly two
months after the procedure (18). A nonrandomized pro-
spective study compared 54 patients treated with radiofre-
quency ablation with 49 patients treated with DC ablation
(13). The incidence of sudden death was 2% in the DC
group and 3.7% in the radiofrequency group. Kay et al. (7)
recently reported a 3.2% rate of sudden death (five of 156
patients) in a one-year follow-up in a prospective nonran-
domized study. Moreover, Darpo et al. (15) retrospectively
analyzed the incidence of sudden death after radiofrequency
ablation and reported a 1.9% annual incidence of sudden
death. A multicenter study of 585 patients who underwent
DC or radiofrequency ablation (19) and a meta-analysis of
1,181 patients who underwent radiofrequency ablation (20)
reported risks of 1.04% and 2.0% annual sudden death
mortality rates, respectively. However, the combined inci-
dence rate of sudden death and malignant ventricular
arrhythmias was high, ranging from 6.0% to 6.7% (13,14).
In most of these studies, the cause-and-effect relationship
between the procedure and sudden death was difficult to
assess because of the various times between the cardiac
arrest and the procedure and the high prevalence of under-
lying cardiac disease in these populations.
In our study, we observed that the overall incidence of
sudden death after radiofrequency AV node ablation and
permanent pacemaker implantation was 2.7%, and the
incidence of cardiac arrest likely related to the procedure was
1.2%. The 1.2% incidence is similar to results reported by
Darpo et al. (15) and lower than results from other studies.
Although whether the procedure is a cause of sudden death
cannot be precisely determined, the temporal relationship
between the procedure and the event, as strictly defined in
our study, and the detailed pursuit to determine the pres-
ence or absence of comorbid CVDs render the cause-and-
effect relation likely. Other potential explanations for dif-
ferent results among the studies include differences in
patient characteristics, methods, sizes and time frames.
Mechanism of sudden death. It has been conjectured that
the smaller lesion associated with radiofrequency ablation
compared with that associated with DC ablation may lead
to a reduction in the risk of sudden death after AV node
ablation. In patients who underwent DC AV node ablation,
the reported incidence of sudden cardiac death was 2% to
3.8% (13,17). The difference between the incidence of
sudden death in our study and the incidence of sudden
death from DC ablation is not large.
The exact underlying mechanisms of unexpected sudden
death remain elusive. Potential mechanisms include pace-
maker failure in the absence of an escape rhythm (7,21),
ventricular arrhythmias associated with coexisting heart
disease (22–24) or exacerbated repolarization abnormalities
secondary to an abrupt change in heart rate (14,25–27). In
our study, pacemaker function had been normal at last
follow-up in all patients with sudden death; however,
postmortem examination of the pacemaker characteristics
was not available. Although repolarization abnormalities
mediated by bradycardia have been a suspected mechanism
of sudden death after AV node ablation, the complexity and
potential multiple mechanisms of arrhythmogenesis after
AV node ablation are highlighted by the reports of one
patient with cardiac arrest despite a higher pacing rate at 90
beats/min and one sudden death in a patient without under-
lying heart disease (14,25). The patient with sudden death
despite a pacing rate of 90 beats/min also had ischemic heart
disease, CHF and poor left ventricular ejection fraction. The
absolute Q-Tc interval changes after ablation were not signif-
icantly different in six of the seven patients with an escape
rhythm. Nevertheless, such observation does not preclude a
rate-dependent repolarization abnormality as a potential ar-
rhythmogenic mechanism as we now begin to understand the
complex interactions among dispersion of refractoriness, ionic
modulations and autonomic modulations (26,27).
Predictors for sudden death. Risk factors for sudden death
after AV node ablation and pacemaker implantation have
not been thoroughly evaluated in published works. In our
study patients, DM, NYHA functional class (II), ventric-
ular arrhythmia, valvular heart disease and COPD were
independent predictors for sudden death likely or possibly
related to the procedure. Previous studies reported that most
patients who had cardiac arrest had ischemic heart disease,
rheumatic heart disease or COPD. Because of the high
prevalence of ischemic heart disease, CHF and low ejection
fraction in our study patients, these factors were not
independent predictors of early sudden death. The obser-
vation that DM may be an independent predictor for
sudden death is intriguing. Repolarization prolongation
related to oral antihyperglycemic agents (e.g., adenosine
triphosphate-sensitive potassium channel blockers and sul-
fonylurea drugs) has been reported (28). Among the nine
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patients who experienced sudden death, five had DM, and four
were receiving an oral antihyperglycemic agent.
Study limitations. This study should be interpreted in
light of the limitations imposed by the retrospective nature
of the study design. The multivariate model was used in our
study to minimize the effect of baseline differences. In this
study, therapy with ablation and pacemaker was selected for
patients with AF refractory to drug therapy. This selection
was not random. However, inclusion of consecutive patients
minimizes other selection biases. Our study does not com-
pare the risk of sudden death among the various treatments
for maintaining control of ventricular rate or sinus rhythm
in patients with AF. The power of the statistical analysis is
limited by the low event rate.
Clinical implications. This study provides the incidence of
sudden death in patients with drug-refractory AF after
radiofrequency AV node ablation and permanent pacing in
a large group of consecutive patients. The incidence of
sudden death likely or possibly related to the procedure is
2.1% (seven patients), and three of the seven events occurred
within 48 h of the procedure in patients with identifiable
risks. Physicians and patients should be aware of such risk
when considering this therapeutic option. The final decision
is reached by weighing the benefit-risk ratio, while recog-
nizing that therapy with AV node ablation and pacemaker
implantation is highly effective in controlling symptoms in
patients refractory to medical therapy (1–8). This procedure
does not decrease long-term survival when compared with
medical therapy (9). Longer in-hospital monitoring and
observation (i.e., two to three days) should be considered in
patients with DM, COPD, significant ventricular arrhyth-
mia or valvular heart disease.
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